Development of a cabozantinib (Cabometyx)symptom management application for use in patients with renal cancer"; XL184-IST50
Clinical Trial Grant
Awarded By
Exelixis, Inc
Start Date
November 7, 2018
End Date
November 6, 2023
Awarded By
Exelixis, Inc
Start Date
November 7, 2018
End Date
November 6, 2023